Seven Lessons I Learned Working at a Biotech Startup
How early stage can help set you up for big stage.
Next-Gen Partnerships: The Ascent of Advanced Therapies
With added push from the COVID-19 pandemic, investment in promising RNA- and cell and gene therapy-based treatments and technology via industry dealmaking is growing considerably.
Advantage Pharma: Capitalizing on Workforce Lessons
With an increase in drug development, why purpose should be the pharma industry’s secret advantage in the global talent shortage, as the COVID-19 crisis transitions into the endemic stage.
Diversity in Action: Q&A With Reshma Kewalramani
Reshma Kewalramani, MD, FASN, chief executive officer and president of Vertex Pharmaceuticals talks about how she supports the efforts of DE&I within and outside her organization.
Diversity in Action: Q&A With Bob McMahon
Robert McMahon, former president of Merck US Human Health, shares some of the challenges leaders face when grappling with how to transform their organizations to embrace DE&I.
Women and Diversity in Industry C-Suites: New Scorecards Tell the Story
Benchmark study across healthcare sectors measures progress in advancing women and people of color into top leadership roles.
A Dogged Devotion
Saving and transforming as many patients’ lives as possible has been the driving force behind Beth Seidenberg’s audacious career, where she has excelled as a doctor, researcher, and venture capitalist.
Surviving Biotech’s Longest and Steepest Bear Market Ever
What will current stranglehold mean for industry down the line?
The Case for Elevating a Brand’s Price Proposition
Tackling the subjective limits of value proposition.
The Impact of Hybrid Workplace Decisions On DE&I Dynamics
Why their influence on employee representation matters for pharma.
One to Watch: China’s Cell and Gene Therapies Industry
Exploring the market’s emergence on the global stage.
Europe’s New HTA System Spurs More Debate, Concern
Fresh round of discussions around health technology assessment.
New Voices Join Mix
Pharm Exec introduces new monthly columns.
Pharmaceutical Executive, April 2022 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive April 2022 issue in an interactive PDF format.
No Half Measures: How Medical Affairs Can Maximize and Measure Value
Education and knowledge transfer must be prioritized for industry to see sizable improvement in medical affairs.
FDA Maps Strategies to Advance Pharmaceutical Quality
Quality metrics, more domestic production aim to avoid supply disruptions and drug shortages.
